Xtl Biopharmaceuticals (XTLB) Free Cash Flow (2009 - 2024)

Xtl Biopharmaceuticals (XTLB) posted quarterly Free Cash Flow of -$303000.0 for Q4 2024, up 40.35% on a QoQ basis from -$508000.0 in Q2 2016.

Xtl Biopharmaceuticals (XTLB) Free Cash Flow (2009 - 2024) Analysis & Trends

Xtl Biopharmaceuticals (XTLB) has reported Free Cash Flow for 9 consecutive years, with -$303000.0 the latest figure, recorded in Q4 2024.

Quarterly Free Cash Flow changed N/A year-over-year to -$303000.0 in Q4 2024, while the trailing twelve-month figure through Dec 2024 was -$303000.0 (changed N/A YoY) and the FY2025 annual result came in at -$1.0 million, up 34.46% from the prior year.
Free Cash Flow improved to -$303000.0 in Q4 2024 per XTLB's latest filing, from -$508000.0 in the prior quarter.
Over the last five years, Free Cash Flow for XTLB reached as high as -$303000.0 in Q4 2024 and fell as low as -$303000.0 in Q4 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Free Cash Flow (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-19.58 Mn
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	158.09 Mn
4	NuCana	279.75 Bn	279.75 Bn	-	-1.53 Mn
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	1.29 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	848.30 Mn
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-354.95 Mn
10	Xtl Biopharmaceuticals	2.60 Bn	2.60 Bn	-	-

Download Data